Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC and Ipilimumab in Localized Prostate Cancer
NCT02506114Phase 2Terminated
- Start
- Oct 2016
- Primary completion
- Apr 2020
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rilimogene galvacirepvec in prostate cancer (PCa). Started Oct 2016; status: terminated.
02
Drugs
rilimogene galvacirepvec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02506114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506114.